GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Kamada Ltd (NAS:KMDA) » Definitions » Cyclically Adjusted PS Ratio

Kamada (Kamada) Cyclically Adjusted PS Ratio : 1.85 (As of May. 15, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Kamada Cyclically Adjusted PS Ratio?

As of today (2024-05-15), Kamada's current share price is $5.66. Kamada's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was $3.06. Kamada's Cyclically Adjusted PS Ratio for today is 1.85.

The historical rank and industry rank for Kamada's Cyclically Adjusted PS Ratio or its related term are showing as below:

KMDA' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 1.27   Med: 1.76   Max: 2.44
Current: 1.82

During the past years, Kamada's highest Cyclically Adjusted PS Ratio was 2.44. The lowest was 1.27. And the median was 1.76.

KMDA's Cyclically Adjusted PS Ratio is ranked better than
55.84% of 745 companies
in the Drug Manufacturers industry
Industry Median: 2.17 vs KMDA: 1.82

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Kamada's adjusted revenue per share data for the three months ended in Mar. 2024 was $0.638. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $3.06 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Kamada Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Kamada's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kamada Cyclically Adjusted PS Ratio Chart

Kamada Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 2.15 2.03 1.28 1.99

Kamada Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.54 1.76 1.83 1.99 1.84

Competitive Comparison of Kamada's Cyclically Adjusted PS Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Kamada's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kamada's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Kamada's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Kamada's Cyclically Adjusted PS Ratio falls into.



Kamada Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Kamada's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=5.66/3.06
=1.85

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kamada's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Kamada's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.638/129.4194*129.4194
=0.638

Current CPI (Mar. 2024) = 129.4194.

Kamada Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 0.434 100.560 0.559
201409 0.533 100.428 0.687
201412 0.645 99.070 0.843
201503 0.253 99.621 0.329
201506 0.493 100.684 0.634
201509 0.452 100.392 0.583
201512 0.697 99.792 0.904
201603 0.386 100.470 0.497
201606 0.481 101.688 0.612
201609 0.558 101.861 0.709
201612 0.604 101.863 0.767
201703 0.322 102.862 0.405
201706 0.870 103.349 1.089
201709 0.569 104.136 0.707
201712 0.651 104.011 0.810
201803 0.417 105.290 0.513
201806 0.833 106.317 1.014
201809 0.376 106.507 0.457
201812 1.280 105.998 1.563
201903 0.653 107.251 0.788
201906 0.861 108.070 1.031
201909 0.795 108.329 0.950
201912 0.769 108.420 0.918
202003 0.766 108.902 0.910
202006 0.957 108.767 1.139
202009 0.775 109.815 0.913
202012 0.695 109.897 0.818
202103 0.556 111.754 0.644
202106 0.517 114.631 0.584
202109 0.545 115.734 0.609
202112 0.774 117.630 0.852
202203 0.615 121.301 0.656
202206 0.541 125.017 0.560
202209 0.666 125.227 0.688
202212 0.951 125.222 0.983
202303 0.679 127.348 0.690
202306 0.827 128.729 0.831
202309 0.706 129.860 0.704
202312 0.638 129.419 0.638
202403 0.638 129.419 0.638

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Kamada  (NAS:KMDA) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Kamada Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Kamada's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Kamada (Kamada) Business Description

Industry
Traded in Other Exchanges
Address
2 Holzman Street, P.O. Box 4081, Science Park, Rehovot, ISR, 7670402
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, Proprietary Products segment and Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.

Kamada (Kamada) Headlines

From GuruFocus

Kamada Announces Planned Transition of Chief Financial Officer

By Value_Insider Value_Insider 12-19-2022